> Details

Meischl, Tobias; Schmid-Scherzer, Karin; Vafai-Tabrizi, Florian; Wurzinger, Gert; Traunmüller-Wurm, Eva; Kutics, Kristina; Rauter, Markus; Grabcanovic-Musija, Fikreta; Müller, Simona; Kaufmann, Norbert; Löffler-Ragg, Judith; Valipour, Arschang; Funk, Georg-Christian

The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry
  • Contributor: Meischl, Tobias; Schmid-Scherzer, Karin; Vafai-Tabrizi, Florian; Wurzinger, Gert; Traunmüller-Wurm, Eva; Kutics, Kristina; Rauter, Markus; Grabcanovic-Musija, Fikreta; Müller, Simona; Kaufmann, Norbert; Löffler-Ragg, Judith; Valipour, Arschang; Funk, Georg-Christian
  • Published: Springer Science and Business Media LLC, 2023
  • Published in: Respiratory Research, 24 (2023) 1
  • Language: English
  • DOI: 10.1186/s12931-023-02338-0
  • ISSN: 1465-993X
  • Origination:
  • Footnote:
  • Description: Abstract Background Alpha-1-antitrypsin (AAT) deficiency (AATD) is a genetic disorder that can manifest as lung disease. A delay between onset of symptoms and diagnosis of AATD is common and associated with worse clinical status and more advanced disease stage but the influence on survival is unclear. Objective We aimed to investigate the impact of diagnostic delay on overall survival (OS) and transplant-free survival (TS) in AATD patients. Methods We analysed 268 AATD patients from the prospective multi-centre Austrian Alpha-1 Lung (AAL) Registry, employing descriptive statistics, Chi-square-test as well as univariable (Kaplan–Meier plots, log-rank test) and multivariable survival analysis (Cox regression). Results The predominant phenotype was Pi*ZZ (82.1%). At diagnosis, 90.2% had an AAT level below 0.6 g/L. At inclusion, 28.2% had never smoked, 68.0% had quit smoking and 3.8% continued to smoke. Lung disease was diagnosed in 98.5%, thereof most patients were diagnosed with emphysema (63.8%) and/or chronic obstructive pulmonary disease (44.0%). Median diagnostic delay was 5.3 years (inter-quartile range [IQR] 2.2–11.5 years). In multivariable analysis (n = 229), a longer diagnostic delay was significantly associated with worse OS (hazard ratio [HR] 1.61; 95% CI 1.09–2.38; p = 0.016) and TS (HR 1.43; 95% CI 1.08–1.89; p = 0.011), independent from age, smoking status, body mass index (BMI), forced expiratory volume in one second (FEV1) and long-term oxygen treatment. Furthermore, BMI, age and active smoking were significantly associated with worse OS as well as BMI, active smoking and FEV1 were with worse TS. Conclusions A delayed diagnosis was associated with significantly worse OS and TS. Screening should be improved and efforts to ensure early AATD diagnosis should be intensified.
  • Access State: Open Access